Obermatt
See Similar Stocks →

Celldex Therapeutics

NAQ:CLDX · US15117B2025
BiotechnologySmall

360

52
Medium confidence — indicative
Profit price46
Owner Earnings Yield1
Dividend Yield1
Price/Sales12
Price/Book15
Return on Capital19
Cash Return on Capital23
Return on Equity35
Profit margins1
Accruals93
Owner Earnings Margin1
Sales growth74
Profit growth6
Reinvestment17
Price momentum42
Debt load91
Refinancing49
Debt Payback1
Liquidity59
Analyst ratings57
Opinion Changes50
Price Target Upside61
Market mood85
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Celldex Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees207
Websitecelldex.com
ISINUS15117B2025
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Chronic DiseasesDermatologyImmunologyStem Cell TherapyRespiratoryInflammationAllergyBiotechnologyHealth CarePharmaceutical

Description

Celldex Therapeutics, Inc. (Celldex) operates as a biopharmaceutical company. The company is dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/o…

Analysis

Middle-of-the-road

Celldex Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 0/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
71
2026

All-time high

71

Jun 2026

All-time low

58

Mar 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
—
—
—
Price/Earnings
74
—
—
—
Price/Book
15
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
8
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Celldex Therapeutics with its peers
Apogee Therapeutics
NMQ:APGE
58
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Eupraxia Pharmaceuticals
TOR:EPRX
—
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sana Biotechnology
NSQ:SANA
63
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Century Therapeutics
NAQ:IPSC
45
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dianthus Therapeutics
NAQ:DNTH
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Assembly Biosciences
NSQ:ASMB
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →